PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
在KOL洞察手术部位感染预防方面，Polypid对SHIELD II试验进行更新
- After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels
- Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs
- Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
- Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
- 在 COVID 期间，手术部位感染（SSI）发病率降低了，但现在上升，预示着回到 COVID 之前的水平。
- 已知的程序和患者风险因素显著增加了 SSIs 的风险并影响了支付者的费用。
- SHIELD II 计划招募总计 600 个受试者中的约 250 名患者。
- 大约有 400 名患者完成了 30 天的随访后，将进行解盲的中期分析。到 2025 年第一季度将公布头条结果。2025 年第一季度公布结果。